Kexing Biopharm Co.,Ltd.

27/11/2025

🥳 Warm Thanksgiving wishes from Kexing!

🥰 We are profoundly thankful with deep gratitude on our global teams, partners and customers who champion health innovation. Your unwavering support inspires us daily.

💖 Wishing you abundant joy, cherished moments with loved ones, and a future filled with prosperity and well-being.

12/11/2025

✅ GB10, a novel multi-target antibody fusion protein: targeting and inhibiting the two key pathogenic factors, VEGF and Ang-2, while formulating a high-concentration preparation (140 mg/mL). Our research on its novel antibody fusion protein GB10 project—targeted at anti-choroidal neovascularization diseases—in the renowned international pharmacology journal Biomedicine & Pharmacotherapy.

✅ As a dual-pathway drug simultaneously targeting VEGF and Ang-2, GB10 offers significant advantages, including multi-target blockade, superior in vitro potency, enhanced in vivo efficacy, prolonged duration of action, and ultra-high-concentration formulations. Read more: https://www.kexingbiopharm.com/news-and-information/ophthalmic-innovative-drug.html

Recently, Kexing Biopharm (688136.SH) announced the publication of key research findings on its novel antibody fusion protein GB10 project—targeted at anti-choroidal neovascularization diseases—in the renowned international pharmacology journal Biomedicine & Pharmacotherapy.

05/11/2025

🎉🎉 Kexing Biopharm’s GB18 Enters Phase I Clinical Study in China

👍 Kexing Biopharm (stock code: 688136.SH), its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has completed the first subject enrollment for the Phase I clinical study of GB18 Injection in China, marking a new milestone in the program’s development.

✅ GB18 is an innovative biologic targeting GDF15 (Growth Differentiation Factor 15), designed for the potential treatment of cancer cachexia. The molecule utilizes a Fc-fusion nanobody structure to enhance stability, bioavailability, and dosing convenience.

💪 GB18 represents an important step in Kexing Biopharm’s innovation pipeline. The company remains committed to advancing novel biologics that address unmet clinical needs and to accelerating the global development of its research programs.

31/10/2025

🔥🔥 Kexing Biopharm's CPHI adventure concludes successfully! 🔥🔥

🌍🌏 Kexing Biopharm's Hall3.1 D31 closing day packed with global partners buzzing on innovations!
🎥🎥 Video relives innovation sparks & partner handshakes. Pharma's horizon endless!

29/10/2025

🔥🔥 CPHI Frankfurt is on fire! 🔥🔥

🎉 Kexing Biopharm's Hall 13.1 D31 booth buzzing with crowds – biopharma innovation stealing the show!

Check the video for global partners uniting.
What's your take? Join the chat! 💪👀

27/10/2025

🤩 CPHI Frankfurt: 1 Day Countdown! 🤩

🥳 Kexing Biopharm welcomes you to Hall3.1 D31 for global biopharma frontiers.
🆙 Oct 28-30th, 2025 – Let's collaborate!

24/10/2025

🚀🚀 Only 4 Days Left to CPHI Frankfurt!
😀 Kexing Biopharm invites you to Hall3.1 D31 to explore global biopharma opportunities. Oct 28-30th, 2025 – Let's connect! 🥳🥳

23/10/2025

🎉🎉 Kexing Biopharm Partners with BioDlink to Embark on Latin American Markets
—— Bevacizumab's First batch Successfully Shipped to Colombia.

🎐 Recently, the first batch of orders for Kexing Biopharm (stock code: 688136.SH)'s bevacizumab biosimilar was successfully shipped to Colombia — licensed-in by BioDlink. This represents the product's first overseas commercialization shipment following marketing approval.

✅ Bevacizumab is a commonly used drug in the oncology field, indicated worldwide for the treatment of various cancers. Having just received approval from Colombia's drug regulatory authority (INVIMA) not long ago, the rapid shipment just over two months later not only highlights the efficient international registration and supply capabilities of both partners but also brings new treatment options to local patients.

🚀 As an important pharmaceutical market in Latin America, Colombia boasts a well-established regulatory system and highly internationalized drug evaluation standards. Kexing Biopharm will use Colombia as a starting point to continuously advance the registration and commercialization of bevacizumab in the Latin American market.

💪 Through this collaboration, leveraging BioDlink's high-standard production and quality systems, as well as Kexing Biopharm's professional expertise in international registrations and market promotion, the two parties will continue to join hands to drive the global layout of more high-quality drugs, providing more accessible treatment solutions for patients worldwide.

21/10/2025

🚀 We're thrilled to invite you to CPHI Frankfurt 2025!

Kexing Biopharm will be at Booth 3.1D31 from October 28-30th. Explore our latest advancements in biopharmaceuticals, from oncology to infectious diseases, and connect with our team for partnerships and insights. Don't miss the future of pharma innovation - stop by and let's collaborate!

📍 Messe Frankfurt, Ludwig-Erhard-Anlage 16, 60327 Frankfurt am Main, Germany
🌐 www.kexingbiopharm.com

17/10/2025

🎉 Kexing Biopharm Partners with Easton Biopharmaceuticals to Expand Global Access to generic Apalutamide Tablets

💪 Kexing Biopharm (Stock Code: 688136.SH) has entered into a collaboration with Easton Biopharmaceuticals, obtaining exclusive overseas commercialization rights for the generic Apalutamide Tablets in multiple countries across Indonesia, Egypt, Saudi Arabia, and Colombia.

✅ Apalutamide, a second-generation nonsteroidal androgen receptor (AR) inhibitor, is indicated for adult patients with prostate cancer. The therapy has been recognized by several international clinical guidelines.

💥 This partnership follows Kexing’s previous collaboration on Enzalutamide Soft Capsules and represents another step in strengthening its prostate cancer portfolio. Leveraging Easton’s strong R&D and manufacturing capabilities and Kexing’s international registration and commercialization network, both companies aim to accelerate the global availability of high-quality prostate cancer therapies.

🌏 Kexing Biopharm remains committed to its “Global Selection + Global Coverage” strategy, working with partners to enhance the accessibility of innovative and affordable treatments for patients worldwide.

17/10/2025

🎊 Kexing Biopharm Strengthens Middle East Presence at Saudi Arabia (Riyadh) - China (Shenzhen) Medical Device Industry Promotion Conference 🎊

✅ Kexing Biopharm (Stock Code: 688136.SH) attended the Saudi Arabia (Riyadh) - China (Shenzhen) Medical Device Industry Promotion Conference held in Riyadh. Representing the Shenzhen Pharmaceutical and Medical Device Export Consortium, Kexing showcased its international development strategy and signed an important collaboration agreement.

✅During the event, Kexing Biopharm signed a cooperation deal with Pharmaknowl Consulting, a leading Saudi regulatory consulting firm, to advance local regulatory compliance and facilitate market entry for its pharmaceutical portfolio across Saudi Arabia and the wider Middle East region.

✅The Middle East is emerging as one of the world’s most dynamic healthcare markets, with Saudi Arabia serving as a key hub for regional pharmaceutical growth and innovation.

🌏 Kexing Biopharm will continue to deepen its international strategy, working with partners to promote professional, compliant, and localized operations—enhancing global access to high-quality and affordable therapies.

13/10/2025

📢CPHI Frankfurt Countdown📢
Kexing Biopharm sincerely invites you to meet us at CPHI Europe 2025! 🥰
Warm welcome and let us make more opportunity! 🌠🌠

-in-class